Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model

  • Antimicrob Agents Chemother. 2004 Jun;48(6):2318-20. doi: 10.1128/AAC.48.6.2318-2320.2004.
Radhakrishnan P Iyer  1 ,  Arlene Roland ,  Yi Jin ,  Samir Mounir ,  Brent Korba ,  Justin G Julander ,  John D Morrey
Affiliations
  • 1. Origenix Techonologies, Inc., St. Laurent, Quebec, Canada.
PMID: 15155244 DOI: 10.1128/AAC.48.6.2318-2320.2004
Abstract

ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P </= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.

Products